A multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of Taoren Honghua Jian granule in patients with stable coronary artery disease

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial

The Lancet ◽

10.1016/s0140-6736(17)32458-3 ◽

2018 ◽

Vol 391 (10117) ◽

pp. 205-218 ◽

Cited By ~ 141

Author(s):

Stuart J Connolly ◽

John W Eikelboom ◽

Jackie Bosch ◽

Gilles Dagenais ◽

Leanne Dyal ◽

...

Keyword(s):

Coronary Artery Disease ◽

Coronary Artery ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Rationale, design, and baseline characteristics of the Study assessInG the morbidity-mortality beNefits of the If inhibitor ivabradine in patients with coronarY artery disease (SIGNIFY trial): A randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease without clinical heart failure

American Heart Journal ◽

10.1016/j.ahj.2013.06.024 ◽

2013 ◽

Vol 166 (4) ◽

pp. 654-661.e6 ◽

Cited By ~ 20

Author(s):

Kim Fox ◽

Ian Ford ◽

Philippe Gabriel Steg ◽

Jean-Claude Tardif ◽

Michal Tendera ◽

...

Keyword(s):

Heart Failure ◽

Coronary Artery Disease ◽

Coronary Artery ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Baseline Characteristics ◽

Clinical Heart Failure ◽

Faculty Opinions recommendation of Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.732115137.793543880 ◽

2018 ◽

Author(s):

Gad Cotter ◽

Olga Milo

Keyword(s):

Coronary Artery Disease ◽

Coronary Artery ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Faculty Opinions recommendation of Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1122755.579832 ◽

2008 ◽

Author(s):

Wolfgang Schoels

Keyword(s):

Coronary Artery Disease ◽

Left Ventricular Systolic Dysfunction ◽

Controlled Trial ◽

Systolic Dysfunction ◽

Left Ventricular ◽

Ventricular Systolic Dysfunction ◽

Double Blind ◽

Double Blind Placebo ◽

Exploring the potential of low-dose sulfasalazine in stable coronary artery disease patients: randomized, double-blind, placebo-controlled study

European Heart Journal - Cardiovascular Pharmacotherapy ◽

10.1093/ehjcvp/pvv021 ◽

2015 ◽

Vol 1 (4) ◽

pp. 214-216 ◽

Cited By ~ 3

Author(s):

Kanchan Vohra ◽

Pawan Krishan ◽

Sudhir Varma ◽

Harpreet Singh Kalra

Keyword(s):

Coronary Artery Disease ◽

Coronary Artery ◽

Low Dose ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo ◽

Efficacy of perindopil in reduction of cardiovascular events among patients with stable coronary artery disease: randomized, double-blind, placebo-controlled, multicenter trial (the EUROPA study)

ACC Current Journal Review ◽

10.1016/j.accreview.2003.10.008 ◽

2004 ◽

Vol 13 (1) ◽

pp. 21

Keyword(s):

Coronary Artery Disease ◽

Coronary Artery ◽

Cardiovascular Events ◽

Multicenter Trial ◽

Double Blind ◽

Double Blind Placebo ◽

The efficacy and safety of Shenzhu Guanxin Recipe Granules for the treatment of patients with coronary artery disease: protocol for a double-blind, randomized controlled trial

Trials ◽

10.1186/s13063-019-3629-4 ◽

2019 ◽

Vol 20 (1) ◽

Cited By ~ 1

Author(s):

Xiao Jin ◽

Biqi Pan ◽

Huanlin Wu ◽

Bingxin Wu ◽

Yukai Li ◽

...

Keyword(s):

Coronary Artery Disease ◽

Randomized Controlled Trial ◽

Coronary Artery ◽

Controlled Trial ◽

Efficacy And Safety ◽

Double Blind ◽

Randomized Controlled ◽

Effect of Clarithromycin Treatment on Chlamydia pneumoniae in Vascular Tissue of Patients with Coronary Artery Disease: a Randomized, Double-Blind, Placebo-Controlled Trial

Journal of Clinical Microbiology ◽

10.1128/jcm.43.3.1325-1329.2005 ◽

2005 ◽

Vol 43 (3) ◽

pp. 1325-1329 ◽

Cited By ~ 5

Author(s):

H. F. Berg ◽

B. Maraha ◽

A. van der Zee ◽

S. K. Gielis ◽

P. J. M. Roholl ◽

...

Keyword(s):

Coronary Artery Disease ◽

Coronary Artery ◽

Chlamydia Pneumoniae ◽

Vascular Tissue ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo ◽

A randomized double-blind placebo-controlled trial of the effect of homocysteine-lowering therapy with folic acid on endothelial function in patients with coronary artery disease

ACC Current Journal Review ◽

10.1016/s1062-1458(01)00465-2 ◽

2001 ◽

Vol 10 (6) ◽

pp. 31-32

Author(s):

J Thambyrajah ◽

M.J Landray ◽

H.J Jones ◽

F.J McGlynn ◽

D.C Wheeler ◽

...

Keyword(s):

Coronary Artery Disease ◽

Folic Acid ◽

Coronary Artery ◽

Endothelial Function ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Lowering Therapy ◽

Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial

The Lancet ◽

10.1016/s0140-6736(08)61170-8 ◽

2008 ◽

Vol 372 (9641) ◽

pp. 807-816 ◽

Cited By ~ 694

Author(s):

Kim Fox ◽

Ian Ford ◽

P Gabriel Steg ◽

Michal Tendera ◽

Roberto Ferrari

Keyword(s):

Coronary Artery Disease ◽

Left Ventricular Systolic Dysfunction ◽

Controlled Trial ◽

Systolic Dysfunction ◽

Left Ventricular ◽

Ventricular Systolic Dysfunction ◽

Double Blind ◽

Double Blind Placebo ◽